¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"plasma thromboplastic factor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • dilution factor
    Èñ¼®ÀÎÀÚ
  • exclusion of confounding factor
    ±³¶õ¹èÁ¦ÀÎÀÚ
  • exogenous factor
    ¿ÜÀοä¼Ò
  • extrinsic factor
    ¿ÜÀÎÀÎÀÚ, ¿ÜÀÎÀÚ
  • elongation factor
    ´ÃÀÓÀÎÀÚ, ¿¬ÀåÀÎÀÚ
  • endothelium-derived contracting factor
    ³»ÇÇÀ¯·¡¼öÃàÀÎÀÚ
  • endothelium-derived relaxing factor
    ³»ÇÇÀ¯·¡ÀÌ¿ÏÀÎÀÚ
  • endurance factor
    °ßµõÀÎÀÚ
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ
  • fermentation factor
    ¹ßÈ¿ÀÎÀÚ
  • fertility factor
    ¼öÅÂÀÎÀÚ
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibroblast growth factor
    ¼¶À¯¸ð¼¼Æ÷¼ºÀåÀÎÀÚ
  • factor
    1. ÀÎÀÚ 2. ¿äÀÎ 3. °è¼ö
  • factor III
    Á¦3ÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • elongation factor
    ´ÃÀÓÀÎÀÚ, ¿¬ÀåÀÎÀÚ
  • endothelium-derived contracting factor
    ³»ÇǼ¼Æ÷¼öÃàÀÎÀÚ
  • endothelium-derived relaxing factor
    ³»ÇǼ¼Æ÷ÀÌ¿ÏÀÎÀÚ
  • endurance factor
    Áö¼ÓÀÎÀÚ
  • eosinophil chemotactic factor
    È£»ê±¸È­ÇÐÁÖ¼ºÀÎÀÚ, È£»ê±¸È­Çнò¸²ÀÎÀÚ
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ
  • exogenous factor
    ¿ÜÀοä¼Ò
  • extrinsic factor
    ¿ÜÀÎÀÎÀÚ, ¿ÜÀÎÀÚ
  • factor
    ÀÎÀÚ, ¿äÀÎ, °è¼ö
  • factor theory
    ¿äÀÎÀÌ·Ð
  • fermentation factor
    ¹ßÈ¿ÀÎÀÚ
  • fertility factor
    ¼öÅÂÀÎÀÚ
  • fibrin stabilizing factor
    ¼¶À¯¼Ò¾ÈÁ¤ÀÎÀÚ
  • fibroblast growth factor
    ¼¶À¯¸ð¼¼Æ÷¼ºÀåÀÎÀÚ
  • granulocyte colony-stimulating factor
    °ú¸³±¸Áý¶ôÀÚ±ØÀÎÀÚ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • plasma protein
    Ç÷Àå´Ü¹éÁú(úìíìÓ±ÛÜòõ).
  • plasma protein
    Ç÷Àå´Ü¹é(Áú)
  • plasma protein binding
    Ç÷Àå´Ü¹é°áÇÕ.
  • plasma protein fraction =PCC
    Ç÷Àå´Ü¹éºÐȹ
  • plasma prothrombin time
    Ç÷ÀåÇÁ·ÎÆ®·Òºó ½Ã°£.
  • plasma renin activity
    Ç÷Àå·¹´ÑȰ¼ºµµ<--Ȱµ¿µµ>
  • plasma substitute
    Ç÷Àå´ë¿ëÁ¦.
  • plasma thrombokinin
    Ç÷À寮·Òº¸Å°´Ñ.
  • plasma thromboplastin
    Ç÷À寮·Òº¸ÇÃ¶ó ½ºÆ¾.
  • plasma thromboplastin antecedent
    Ç÷À寮·Òº¸ÇÃ¶ó½ºÆ¾Àü±¸(îñÏÌ)¹°Áú
  • plasma thromboplastin antecedent =PTA
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾Àü±¸¹°Áú (
  • plasma thromboplastin component =PTC
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¼ººÐ(¡­à÷ÝÂ
  • plasma thromboplastin component defic
    ÇöóÁ<Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¼ººÐ°áÇÌ(Áõ
  • plasma thromboplastin inhibitor
    ÇöóÁ <Ç÷Àå>Æ®·Òº¸ÇÃ¶ó½ºÆ¾¾ïÁ¦¹°Áú.
  • plasma turnover
    Ç÷À屳ü(úìíìÎßôð)
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • plasma iron disappearance
    Ç÷Àåö¼Ò½Ç(úìíìôÑá¼ã÷).
  • plasma iron disappearance rate
    Ç÷Àåö¼Ò½Ç·ü(úìíìôÑá¼ã÷ëÒ).
  • plasma iron pool
    Ç÷ÀåöÀúÀå°í.
  • plasma iron turnover
    Ç÷Àåö±³Ã¼
  • plasma iron turnover rate
    Ç÷Àåö±³Ã¼À².
  • plasma lipoprotein abnormalities
    Ç÷ÀåÁöÁú´Ü¹éÁúÀÌ»óÁõ.
  • plasma membrane
    ¿øÇüÁú¸·(ê«û¡òõد), ¼¼Æ÷ÇüÁú¸·(á¬øàû¡òõد).
  • plasma membrane
    ¿øÇüÁú¸·
  • plasma membrane
    ÇüÁú¸·
  • plasma membrane
    ¿øÇüÁú¸·(ê«û¡òõد), ¼¼Æ÷ÇüÁú¸·(á¬øàû¡òõد).
  • plasma membrane
    ÇüÁú¸·
  • plasma membrane carnitine transport defect
  • plasma membrane of erythrocyte
    ÀûÇ÷±¸ÇüÁú¸·
  • plasma pepsinogen
    Ç÷ÀåÆé½Ã³ë°Õ
  • plasma protein
    Ç÷Àå´Ü¹é(Áú)
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
  • colony-stimulating factor
    ÄݷδÏÀÚ±Ø ÀÎÀÚ(í©Ð½ì×í­)
  • contact factor
    "Á¢ÃËÀÎÀÚ(ïÈõºì×í­), (ÔÒ) Hageman factor"
  • conversion factor
    ÀüȯÀÎÀÚ(ï®üµì×í­)
  • cord factor
    ÄÚµå ÀÎÀÚ(ì×í­)
  • coupling factor
    ¦Áþ±â ÀÎÀÚ(ì×í­)
  • decay factor
    "ºØ±« ÀÎÀÚ(ÝÚÎÕì×í­), (ÔÒ) decay constant"
  • diffusing factor
    "È®»êÀÎÀÚ(üªß¤ì×í­), (ÔÒ) hyaluronidase"
  • dissociation factor
    ÇØ¸®ÀÎÀÚ(ú°×îì×í­)
  • egg white injury factor
    ÈØÀÚ ¼Õ»óÀÎÀÚ (áßß¿ì×í­)
  • elongation factor
    ¿¬ÀåÀÎÀÚ (æÅíþì×í­)
  • epidermal growth factor
    Ç¥ÇǼºÀåÀÎÀÚ (øúù«à÷íþì×í­)
  • epithelial growth factor
    »óÇǼºÀåÀÎÀÚ (ß¾ù«à÷íþì×í­)
  • erythrocyte maturation factor
    ÀûÇ÷±¸ ¼º¼÷ ÀÎÀÚ (îåúìϹà÷âÙì×í­)
  • extrinsic factor
    ¿ÜÀÎÀÚ(èâì×í­)
  • factor
    ÀÎÀÚ(ì×í­)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
PRF partial reinforcement; patient report form; perforin; plasma recognition factor; pontine reticular f...
LP labile peptide; labile protein; laboratory procedure; lactic peroxidase; lamina propria; laryngophar...
L/P lactate/pyruvate [ratio]; liver plasma [concentration]; lymph/plasma [ratio]
PA panic attack; pantothenic acid; paralysis agitans; paranoia; passive aggressive; pathology; patient'...
PC avoirdupois weight [Lat. pondus civile]; packed cells; paper chromatography; paracortex; parent cell...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 5
P Plasma
PV Plasma
pl Plasma
PAVP Plasma AVP
PA Plasma Aldosterone
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • constitutional factor
    ±¸¼º ¿ä¼Ò, üÁú ¿äÀÎ
  • contributing factor
    ±â¿© ¿äÀÎ
    ÁúȯÀ̳ª Àå¾Ö¸¦ À¯¹ßÇϰųª ¾ÇÈ­Çϴµ¥ ±â¿©ÇÏ´Â »óųª Çൿ.
  • conversion factor
    º¯È¯ °è¼ö
  • cooperative factor
    Çùµ¿ ÀÎÀÚ
  • coronary risk factor
    °ü»ó µ¿¸Æ Áúȯ À§Çè ¿äÀÎ
  • cothromboplastin factor VII
    ÄÚÆ®·Ò º¸ÇÃ¶ó½ºÆ¾
  • coupling factor
    ¹è¿ì ÀÎÀÚ
  • covering factor
    ÇǺ¹ ÀÎÀÚ
  • cultural and ethnic factor
    ¹®È­ ¹ÎÁ·Àû ¿äÀÎ
  • cytotoxic factor
    ¼¼Æ÷ µ¶¼º ÀÎÀÚ
  • D and C ÀÚ±ÃÀÇ °æºÎ È®Àå°ú ³»¸· ¼ÒÆÄ.

    D factor

    D-ÀÎÀÚ
  • Decay accelerating factor
    ºØ±« °¡¼Ó ¿ä¼Ò
  • diabetogenic factor
    ´ç´¢ À¯¹ß ÀÎÀÚ
  • differentiation factor
    °¨º° ¿äÀÎ, °¨º° ¿ä¼Ò, °¨º° ÀÎÀÚ
  • diffusion factor
    È®»ê ÀÎÀÚ
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 5
human plasma protein fraction A sterile solution of selected proteins derived from the blood plasma of adult human donors, containing 4.5 to 5.5 g of protein per 100 ml, of which 83 to 90% is albumin and the remainder is alpha-and beta-globulins; used as a blood volume supporter.
(05 Mar 2000)
standing plasma test If plasma is stored at 4°C upright in a test tube, chylomicrons will float to the top and form a creamy layer.
(05 Mar 2000)
normal human plasma Sterile plasma obtained by pooling approximately equal amounts of the liquid portion of citrated whole blood from eight or more adult humans who have been certified as free from any disease which is tranmissible by transfusion, and treating it with ultraviolet irradiation to destroy possible bacterial and viral contaminants.
(05 Mar 2000)
dried human plasma protein fraction Freeze-dried human plasma protein fraction.
(05 Mar 2000)
d-shaped plasma <radiobiology> A toroidal plasma whose cross-section (poloidal plane) is a D (instead of a circle). A D-shape has a higher beta limit than a circular shape.
(09 Oct 1997)
quasineutral plasma <physics> An ionised gas in which positive and negative charges are present in approximately equal numbers.
(09 Oct 1997)
interstitial plasma cell pneumonia <chest medicine> A pneumonia caused by an infection with Pneumocystis carinii.
Pneumocystis carinii grows rapidly in the lungs of patients with immunosuppression, particularly due to AIDS and is the leading AIDS-related cause of death. Pneumocystis carinii infection sometimes may occur elsewhere in the body (skin, eye, spleen, liver or heart).
It is considered one of the diagnostic criteria for AIDS in an HIV positive individual.
(10 Jan 1998)
target plasma <radiobiology> Plasma used to trap a neutral atom beam. A background plasma of sufficiently high density and temperature can ionize neutral atoms more effectively than the Lorentz process (where v cross B creates effective electric field).
(09 Oct 1997)
temperature, plasma <radiobiology> A measure of the random (thermal) kinetic energy of the ions or electrons in the plasma. The temperature of each component of a plasma depends on the mean kinetic energy of that component. An example of this is the fluorescent light bulb, which is an example of a weakly-ionised plasma where the electrons are at temperatures of tens of thousands of degrees, whereas the ions and neutrals are much cooler (so that you can touch the bulb without being burned).
See: atomic temperature, electron temperature, ion temperature.
(09 Oct 1997)
edge plasma <radiobiology> Cooler, less dense plasma away from the centre of a reactor, affected by limiter or divertor, includes scrape-off layer. Distinguished from core plasma.
(09 Oct 1997)
effective renal plasma flow <physiology> The amount of plasma flowing to the parts of the kidney that have a function in the production of constituents of urine; the clearance of substances such as iodopyracet and p-aminohippuric acid, assuming that the extraction ratio in the peritubular capillaries is 100%.
It is the amount of plasma perfusing the kidney tubules per unit time, generally measured by p-aminohippurate clearance. It should be differentiated from renal plasma flow which is approximately 10% greater than the effective renal plasma flow.
(07 Mar 2000)
two-component plasma <radiobiology> Refers to a plasma containing a cool thermal component and a population of high energy particles (such as from neutral beam injection) which are in the process of thermalising (slowing down).
(09 Oct 1997)
kern-plasma relation theory A theory enunciated by Hertwig (1903) that a definite relation as to size normally exists in every cell between the mass of nuclear material and that of the protoplasm.
Origin: Ger. Kern, kernel, nucleus
(05 Mar 2000)
fresh frozen plasma The fluid component of blood lacking the cells but containing all the necessary plasma proteins, used to restore the protein clotting factors in some individuals with clotting factor deficiencies.
(27 Sep 1997)
accelerator factor <chemical> Heat- and storage-labile plasma glycoprotein which accelerates the conversion of prothrombin to thrombin in blood coagulation. Factor v accomplishes this by forming a complex with factor xa, phospholipid, and calcium (prothrombinase complex). Deficiency of factor v leads to owren's disease.
Chemical name: Blood-coagulation factor V
(12 Dec 1998)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 5
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 5
ÅëÇÕ°Ë»ö ¿Ï·á